NCT00285766

Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (planned)
• Sponsor: Somerset Pharmaceuticals · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.

Conditions

• Major Depression

Interventions

Type	Name	Description
DRUG	Selegiline Transdermal System

Timeline

• Start date: 2002-08-01
• Completion: 2005-07-01
• First posted: 2006-02-02
• Last updated: 2008-04-22

Locations

15 sites across 1 country: United States